RECISTv1.1 progression in oncology: Shades of gray. Academic Article uri icon

Overview

abstract

  • The Response Evaluation Criteria in Solid Tumors (RECIST)-based outcomes, such as objective response rate (ORR) or progression free survival (PFS), are standard outcomes for early oncology trials. These indices provide a black-and-white interpretation of response to therapy. We propose that lesion-level analysis and mechanism-based pharmacodynamic endpoints may provide a more informative index of response to therapy. Accounting for "shades of gray" in lesion-level response assessments may reduce bias in go/no-go decisions and biomarker analyses for novel oncology compounds and discontinuation decisions for individual patients.

publication date

  • April 30, 2023

Research

keywords

  • Neoplasms

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2023.04.012

PubMed ID

  • 37172579